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In the last row of Table [7](#Tab1){ref-type="table"}, the fracture incidence data for the placebo and drug groups were the wrong way around. The correct rates are 2.5% for the placebo group and 1.4% for the zoledronic acid group. The corrected table is reproduced here. Table 7Study details and antifracture efficacy (relative risk \[RR\] and 95% confidence intervals \[CI\]) of the major pharmacological treatments used for postmenopausal osteoporosis when given with calcium and vitamin D, as derived from randomized controlled trialsInterventionStudyEntry criteriaMean age (years)Number of patients randomisedFracture incidence (percentage over 3 years)^d^RR (95%CI)PlaceboDrugVertebral fracture (high-risk population) Alendronate 5--10 mg\[51\]Vertebral fractures, BMD ≤ 0.68 g/m^2^712,02715.08.00.53 (0.41--0.68) Risedronate 5 mg\[55\]2 vertebral fractures or 1 vertebral fracture and T-score ≤−2.0692,45816.311.30.59 (0.43--0.82) Risedronate 5 mg\[56\]2 or more vertebral fractures--no BMD entry criteria711,22629.018.00.51 (0.36--0.73) Raloxifene 60 mg\[45\]Vertebral fractures--no BMD entry criteria667,70521.214.70.70 (0.60--0.90) Teriparatide 20 μg^a^\[65\]Vertebral fractures and FN or LS T-score ≤−1 if less than 2 moderate fractures691,63714.05.00.35 (0.22--0.55) Ibandronate 2.5 mg\[58\]Vertebral fractures and LS −5\< T-score ≤−2.0692,9469.64.70.38 (0.25--0.59) Ibandronate 20 mg\[59\]Vertebral fractures and LS −5\< T-score ≤−2.0707089.64.90.50 (0.34--0.74) Strontium ranelate 2 g\[68\]Vertebral fractures, LS BMD ≤ 0.840 g/m^2^691,64932.820.90.59 (0.48--0.73) Zoledronic acid 5 mg\[63\]FN T score ≤ −2.5, ± vertebral fracture, or T-score ≤ −1.5 and 2+ mild or 1 moderate vertebral fracture737,76510.93.30.30 (0.24--0.38)Vertebral fracture (low-risk population) Alendronate 5--10 mg^b^\[54\]FN T-score ≤−2684,4323.82.10.56 (0.39--0.80) Alendronate 5--10 mg^b^\[54\]Subgroup of women, T-score \<2.5NA1,6314.02.00.50 (0.31--0.82) Raloxifene 60 mg\[45\]FN or LS T-score ≤−2.5, ± vertebral fractures667,7054.52.30.50 (0.40--0.80)Hip fracture Alendronate 5--10 mg\[51\]Vertebral fractures with BMD ≤ 0.68 g/m^2^712,0272.21.10.49 (0.23--0.99) Alendronate 5--10 mg^b^\[54\]FN T-score ≤−2^c^684,4320.80.70.79 (0.43--1.44) Alendronate 5--10 mg^b^\[54\]FN T-score ≤ − 2.5^c^ (subgroup analysis)NA1,6311.60.70.44 (0.18--1.97) Risedronate 2.5 and 5 mg\[57\]T-score \<−3^c^ or \<−2^c^ and ≥1 non-skeletal risk factor for hip fracture (subgroup analysis osteoporotic patients 70--79 years)779,3313.21.90.60 (0.40--0.90) Raloxifene 60 and 120 mg\[45\]FNorLST-score ≤−2.5, ± vertebral fractures667,7050.70.81.10 (0.60--1.90) Strontium ranelate 2 g\[69\]Osteoporosis (T-score \< −2.5) with or without prior fracture774,9323.42.90.85 (0.61--1.19) Strontium ranelate 2 g\[69\]Age ≥ 74 with T-score ≤−2.4^c^ (subgroup analysis)801,9776.44.30.64 (0.412--0.997) Zoledronic acid 5 mg\[63\]FN T score ≤ −2.5 or less, ± vertebral fracture, or T-score ≤ −1.5 and 2+ mild or 1 moderate vertebral fracture737,7652.51.40.59 (0.42--0.83)FN: femoral neck; LS: lumbar spine: NA: not available^a^20-month study^b^4.2-year study^c^BMD adjusted to NHANES population^d^Except where indicated in column 1

The online version of the original article can be found at: <http://dx.doi.org/10.1007/s00198-008-0560-z>.
